US8551957 — Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2029-10-14 · 3y remaining
What this patent protects
This patent protects a pharmaceutical composition that combines a glucopyranosyl-substituted benzene derivative with a DPP IV inhibitor for treating or preventing certain metabolic disorders.
USPTO Abstract
The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2730 |
— | Jardiance |
U-2730 |
— | Jardiance |
U-1651 |
— | Jardiance |
U-1651 |
— | Jardiance |
U-2730 |
— | Jardiance |
U-1651 |
— | Jardiance |
U-1651 |
— | Jardiance |
U-2730 |
— | Jardiance |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.